Shoba M Amarnath

US Patent:

20120251514, Oct 4, 2012

Filed:

Nov 12, 2010

Appl. No.:

13/509476

Inventors:

Daniel Fowler - Bethesda MD, US
Shoba Amarnath - North Bethesda MD, US
Jeffrey Medin - Toronto, CA
James Chian Ming Wang - Scarborough, CA

Assignee:

University Health Network - Toronto ON
The United States of America, as rep. by the Sec. Department of Health and Human Services - Bethesda MD

International Classification:

A61K 31/7088
C12N 15/867
C12N 5/10
C12N 1/15
A61P 37/06
C12N 1/21
C12N 1/11
C12N 15/62
A61K 35/14
C12N 15/63
C12N 1/13

US Classification:

424 9371, 4353201, 435419, 43525411, 4352572, 4352523, 4352581, 435366, 43525233, 435361, 435365, 435369, 435325, 435372, 4353723, 536 232, 514 44 R

Abstract:

The invention provides nucleic acids comprising a nucleotide sequence encoding programmed death ligand-1 (PD-L1) and a nucleotide sequence encoding a fusion protein comprising thymidylate kinase (TMPK) or a variant thereof and a cell surface marker or a variant thereof. Recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and kits relating to the nucleic acids are disclosed. Methods of treating or preventing a disease in a host and methods of suppressing an immune system in a host are also disclosed.

US Patent:

20210277356, Sep 9, 2021

Filed:

Oct 19, 2020

Appl. No.:

17/074200

Inventors:

- Philadelphia PA, US
- Bethesda MD, US
Shoba Amarnath - Washington DC, US

International Classification:

C12N 5/0783
A61K 35/17

Abstract:

The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.

US Patent:

20170211042, Jul 27, 2017

Filed:

Mar 31, 2017

Appl. No.:

15/476476

Inventors:

- Philadelphia PA, US
- Bethesda MD, US
Shoba Amarnath - Washington DC, US

International Classification:

C12N 5/0783
A61K 35/17

Abstract:

The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.

US Patent:

20140341933, Nov 20, 2014

Filed:

Nov 20, 2012

Appl. No.:

14/359764

Inventors:

- Philadelphia PA, US
- Bethesda MD, US
Shoba Amarnath - Washington DC, US

International Classification:

C12N 5/0783

US Classification:

4241841, 435373, 435325

Abstract:

The present invention provides methods and compositions for converting a T cell into a cell that exhibits at least one regulatory T cell phenotype. The converted T cell is generated by contacting a T cell with a cell that is modified to comprise an agent capable of activating PD1 signaling in a T cell. The converted T cell is useful for preventing, suppressing, blocking or inhibiting an immune response. For example the converted T cell is useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft versus host disease. The converted T cell can also be used to treat autoimmune diseases.